Aging and Alzheimer’s disease: Comparison and associations from molecular to system level

Xian Xia1,* | Quanlong Jiang1,* | Joseph McDermott1 | Jing-Dong J. Han1

Correspondence
Jing-Dong J. Han, 320 Yue Yang Road, Shanghai, 200031, China. Email: jdhan@picb.ac.cn

Funding information
China Ministry of Science and Technology, Grant/Award Number: 2015CB964803, 2016YFE0108700; National Natural Science Foundation of China, Grant/Award Number: 91749205, 91519330; Chinese Academy of Sciences, Grant/Award Number: XDA01010303 XDB19020301

1 | INTRODUCTION

Aging is the time-dependent physiological functional decline that is also the most profound risk factor for many noninfectious diseases, including Alzheimer’s disease (AD). With the growing aging population and increasing burden of health care for people with AD, research on this disease is rapidly expanding. Given the fact that Alzheimer’s disease is one of the best known aging-linked diseases, in this review, we examine how AD is linked to aging and how the research in the two fields could impact and inspire each other, at the molecular, cellular, and system level.

Alzheimer’s disease was first described by the psychiatrist and neuropathologist Alois Alzheimer in 1907 as a disease that manifested extracellular amyloid plaques and intracellular neurofibrillary tangles (NFTs) in the brain, composed of abnormally folded amyloid-β (Aβ42) and tau proteins, as the most pathologically important phenotypic hallmarks. Meanwhile, NFTs are universally found in all aged people and abnormally phosphorylated tau protein is already present in young individuals who do not have AD (Braak & Tredici, 2011). Amyloid plaques are also not unusual in normal brain aging. Other phenotypes of AD include neuronal dystrophy, reactive astrogliosis, synapse loss, and vascular alterations. Although much research has been devoted to biochemical mechanisms of pathogenic events induced by Aβ42 and abnormal tau, the actual cause of AD is still an open question.

2 | MOLECULAR LINKS BETWEEN AGING AND AD

2.1 | Genetic susceptibility

With the advent of next-generation sequencing and genomewide association studies (GWAS), more than 20 risk loci of AD were
identified (Karch & Goate, 2015). However, the identification of apolipoprotein E (APOE), the strongest risk factor for sporadic AD, well preceded the age of high-throughput sequencing. Among the three common alleles (ε2, ε3, and ε4), APOE ε4 is associated with increased AD risk, while APOE ε2 is associated with decreased AD risk (Strittmatter et al., 1993). Other genetic risk loci related to AD can be classified into different functional pathways, including β-amyloid precursor protein loading and sequential cleavage (APP, PSEN1, and PSEN2), cholesterol metabolism (CLU and ABCA7), immune response (CR1, CD33, M5A4, and TREM2), endocytosis (BIN1, PICALM, CD2AP, EphA1, and SORL1), and others (PLD3). A full list of genetic risk factors identified by GWAS of AD can be found in Karch and Goate (2015).

The aging- or longevity-related GWAS have generated few loci, perhaps due to the complexity of the phenotype and the lack of bona fide biomarkers of aging. However, two loci that are repeatedly found by GWAS of aging are APOE (Deelen et al., 2011; Ewbank, 2007; Gerdes, De Jager, & Vaupe, 2000) and FOXO3A (Anselmi et al., 2009; Flachsbart et al., 2009; Li et al., 2009; Pawlikowska et al., 2009; Wilcox et al., 2008). Similar to AD, APOE ε2 is found to be enriched in elderly and centenarians compared to younger individuals (Seripa et al., 2006). Elder APOE ε2 carriers were found to have reduced accumulation of amyloid pathology via multimodal neuroimaging (Grothe et al., 2017). Mice carrying human apoE2-targeted replacement (apoE2-TR) exhibited preserved memory function as compared to apoE3-TR or apoE4-TR mice, but this is independent with age-related synaptic loss or neuroinflammation, and higher level of apoE and lower level of cholesterol in the cortex might contribute to this protective effect (Shinohara et al., 2016).

2.2 DNA methylation

DNA methylation is a well-studied chemical modification which occurs mostly on the 5-carbon of cytosine residues in CG dinucleotides (SmC) of DNA sequence. DNA methylation in promoter regions is correlated with transcriptional repression. Important regulators of DNA methylation include the writers (DNMT1 (maintenance methylation through DNA replication cycle), DNMT3A, DNMT3B, and DNMT3C (Barau et al., 2016) (de novo methyltransferases)), a cofactor without catalytic activity DNMT3L, and erasers (TET1-3). A distinct feature of DNA methylation in brain is that neurons are enriched in mCh (non-CG methylation, H = A/C/T) and 5-hydroxymethylcytosine (5hmC, established by TETs in the first of a series of stepwise modifications (Ito et al., 2011)).

DNA methylation is known to drift away from extremes of complete methylation or demethylation in older people (Heyn et al., 2012), not only intraindividual but also interindividual (Oh et al., 2016). The so-called epigenetic clock in which age is estimated from DNA methylation data is based on the fact that epigenetic age (which is estimated from DNA methylation levels using machine learning algorithms) is highly correlated with chronological age, and thus, the deviation of epigenetic age from chronological age was found to be associated with the severity of cognitive decline in patients with AD (Levine, Lu, Bennett, & Horvath, 2015). Important to note with DNA methylation profiles in AD and brain aging is that the blood methylene might not appear to directly reflect the brain's methylene, at least from the previous data in CD4+ lymphocytes and dorsolateral prefrontal cortex (Yu et al., 2016). Whether this will hold for the whole brain or other brain regions needs further data for support.

Two reports (De Jager et al., 2014; Lunn et al., 2014) established that changes in DNA methylation are associated with AD, and more specifically, a differentially methylated region in ankyrin 1 (ANK1) was found to be associated with the neuropathology. A recent report (Zhao et al., 2017) also links 5mC with AD. Epigenetic changes in AD appear to be independent of genetic variants and therefore influence disease risk by interaction with various genetic factors (Klein & De Jager, 2016). Whether age-related changes in DNA methylation are associated with AD pathology is still unclear. An early study showed that overexpression of Dnmt3a2 isoform could improve the cognitive abilities of aged mice (Oliveira, Hemstedt, & Bading, 2012), which points to the importance of DNA methylation in cognitive function.

2.3 Histone modifications

Histones are the basic building blocks of eukaryotic chromatin, a complex DNA packaging system that helps organize the genome in three-dimensional nuclear space. Histone marks are chemical modifications added to histones, including but not restricted to methylation, acetylation, phosphorylation, ubiquitination, (ADP-)ribosylation, crotonylation, hydroxylation, proline isomerization, and sumoylation (Lardone et al., 2015), to control the expression of genes and to remodel chromosomes.

Chromatin changes during cellular aging are marked by loss of heterochromatin and histone (H1 tail (Funayama, Saito, Tanobe, & Ishikawa, 2006), H3, and H4 (Feser et al., 2010; O’Sullivan, Kubceck, Schreiber, & Karlseder, 2010)) in human cell lines. The overall pattern of histone modifications in aging shows a loss of repressive marks and gain of activating marks (Sen, Shah, Nativio, & Berger, 2016). Although it is not known whether such a pattern exists for in human brain aging, thanks to the Roadmap project, a snapshot of the older brain’s epigenome in seven brain regions (angl gyrus, anterior caudate, cingulate gyrus, dorsolateral prefrontal cortex, inferior temporal cortex, midehippocampus, and substantia nigra) and six marks (H3K9me3, H3K27me3, H3K4me3, H3K36me3, H3K27ac, and H3K4me1) is available. We also refer the readers to reviews on other tissues or model organisms (Booth & Brunet, 2016; Lardone et al., 2015).

Histone acetylation is a major topic in the AD field, as it was found to be drastically decreased in both human (Zhang et al., 2012) and mouse models of AD (Gräff et al., 2012). Indirectly enhancing histone acetylation by chronic inhibition of histone deacetylases (HDACs) was able to reverse the cognitive deficits in AD mouse model (Kilgore et al., 2010) and also in aging mouse (Benito et al., 2015). This is consistent the dysregulation of H4K12ac being
implicated to mediate cognitive impairment in aged mice (Peleg et al., 2010). Other histone markers are reviewed summarized elsewhere (Lardenoije et al., 2015).

2.4 RNA

miRNAs are a class of 22 nt length RNA molecules that negatively regulate mRNA via base pairing mostly in the 3’ untranslated region. The lin-4 miRNA was the first miRNA identified to regulate lifespan in C. elegans, followed by many others (Kato & Slack, 2013). The essentiality of miRNAs in neuronal cells was established by conditional Dicer KO, which is an important enzyme in miRNA genesis. Conditional perturbation experiments of Dicer in mouse brain showed progressive neuronal loss associated with behavioral deficits (Junn & Mouradian, 2012). A pool of miRNAs has been found to be associated with AD at each step of AD pathology or could serve as circulating biomarkers or in diagnostics, such as downregulated miR-132, 212 and upregulated miR-34a and 125b (Millan, 2017; Tan, Yu, Hu, & Tan, 2013), etc.

Long intergenic RNAs (lncRNAs) are a > 200 nt long, poorly conserved, recently discovered, abundant class of noncoding RNAs, transcribed from the intergenic and intronic regions of mammalian genome (Mattick & Rinn, 2015). A recent review summarized the IncRNAs related to senescence and aging process (Kour & Rath, 2016). However, as functions of most of IncRNAs are still unknown, the IncRNAs’ relationship to aging is limited to their expression changes during aging. In contrast to the long list of aging-associated IncRNAs (30 IncRNAs in (Kour & Rath, 2016)), there are only six IncRNAs, BACE1-AS, 51A, 17A, NDM29, BC200, and NAT-Rad18, known to be associated with AD (Luo & Chen, 2016).

RNA editing is the conversion of adenosine to inosine in double-stranded RNA by adenosine deaminases acting on RNA (ADARs) (Nishikura, 2016). In C. elegans, the RNA editomes of wild-type and ADAR mutants were profiled. Worms lacking RNA editing were short-lived, potentially due to alteration of the abundance of proteins, as determined by quantitative proteomics (Zhao et al., 2015). In AD, RNA editing was studied in a site-specific manner (Gaisler-Salomons et al., 2014; Khermesh et al., 2016). Recent research used a preselected set of target sites to quantify A-to-I RNA editing levels and found that the overall editing levels decreased in AD patients’ brain tissues, mainly in the hippocampus (Khermesh et al., 2016).

3 CELLULAR CHANGES IN AGING AND AD

To understand aging and AD, the well-studied molecular changes need to be integrated with the complex cellular context of the brain. In the following section, the roles of neurons, astrocytes, microglia, and oligodendrocytes in aging and AD are examined. Compared with the drastic changes of different cell type compositions and intensive studies in AD, the mild changes of cell types in aging are understudied.

3.1 Neurons

Due to the prevailing neuron-centric view and the clear importance of neuron loss to cognitive deficits, neurons have long been the main focus of brain aging studies. An early study used two-year-old mice (equivalent to the human age group of 65) with two subgroups (5 mice in each group) representing the worst and best performers in the Morris water maze and found that there is no loss of principal hippocampal and subicular neurons (Rasmussen, Schlemm, Sorensen, Zimmer, & West, 1996). A more recent study in human also showed that very old individuals have comparable number of neocortical neurons to younger individuals, while there is significant difference in the total number of neocortical oligodendrocytes (Fabricius, Jacobsen, & Pakkenberg, 2013). Overall, cell counting methods show that significant neuron loss does not occur during normal aging and changes are subtle and region-specific (Burke & Barnes, 2006). A special case in successful aging is cognitive intact elderly with AD pathology, which are believed to have resistant mechanism for Aβ oligomers, and Aβ oligomers are absent from hippocampal postsynapses, while Zn²⁺ levels are lower in such cases (Bjorklund et al., 2012).

AD-related synaptic loss occurs early in the disease process and strongly correlates with cognitive decline (Scheff & Price, 2006). High levels of Aβ have been shown to reduce glutamatergic synaptic transmission and cause synaptic loss, as shown by evidence from both in vivo and in vitro studies (Palop & Mucke, 2010). Aβ can control synaptic activity, depress excitatory transmission at the synaptic level, while triggering aberrant patterns of neuronal circuit activity and epileptiform discharges at the network level (Palop & Mucke, 2010). Using a tauopathy mouse model with in vivo intracellular and extracellular recordings, pathological tau was found to alter neocortical neuronal oscillatory patterns and firing patterns (Menkes-Caspi et al., 2015).

3.2 Glia: astrocytes, oligodendrocytes, and microglia

The simple dichotomy of neuron and glia originates from the historical separation of gray and white matter based on the appearance. With the name originated from the Greek word for glue, glia were for many years viewed simply as the brain’s packing material, holding neurons in place. While there have been some reports on each glia type in AD pathogenesis, astrocytes, which constitute approximately 30% of cells in the mammalian central nervous system, and oligodendrocytes, are hardly studied in the aging process. Brain aging includes proinflammatory phenotypes, altered signaling, and accumulation of senescent microglia (Harry, 2013; Mosher & Wyss-Coray, 2014). Abnormalities in microglial cytoplasmic structure were observed in a case study of two nondemented subjects (one 68-year-old and one 38-year-old) were defined as microglial dystrophy which was further concluded as a sign of microglial cell senescence (Streit, Sammons, Kuhns, & Sparks, 2004). A transcriptional analysis of microglia from discrete brain regions at three different ages in
mouse revealed that microglial aging could happen in a region-specific manner (Grabert et al., 2016).

Reactive astrogliosis is one of the phenotypes of AD, actually noticed by Alois Alzheimer himself, but whether it is beneficial or harmful remains an open question. Astrocytes in Alzheimer's disease show changes in glutamatergic and GABAergic signaling and recycling, potassium buffering, and in cholinergic, purinergic, and calcium signaling (Osborn, Kamphuis, Wadman, & Hol, 2016). Additionally, a subtype of reactive astrocytes is induced by activated neuroinflammatory microglia, which lose most normal astrocytic functions, but gain a neurotoxic function, and is abundant in various human neurodegenerative diseases including Alzheimer's (Liddelow & Barres, 2017).

Oligodendrocytes and myelin are known targets in multiple sclerosis, a neurological disorder (Heppner, Ransohoff, & Becher, 2015). Complement-activated oligodendrocytes are found in various neurodegenerative conditions including AD (Yamada, Akiyama, & McGeer, 1990). Overall, oligodendrocytes, although constituting ~75% of the neuroglia cells in the neocortex, are treated as a silent member of the immune system, which are now emerging as central to AD risk (Guerreiro et al., 2017). Most recently, Zhang et al. (2017) showed that mid-aged mice locally implanted with healthy hypothalamic stem/progenitor cells could retard aging and obtain extended lifespan, which they linked to exosomal microRNA mechanisms.

Changes related to microglia, the macrophages of the CNS, have long been considered to be secondary events to neurodegeneration but are now emerging as central to AD risk (Guerreiro et al., 2013; Jonsson et al., 2013; Lambert et al., 2013; Salter & Stevens, 2017; Zhang et al., 2013). GWAS repeatedly identified SNPs on TREM2, CD33, CD1, etc., which are all expressed on microglia and myeloid cells, as AD risk factors. The actual functions of those SNPs, however, are controversial in different animal models (Heppner et al., 2015). Microglia surround amyloid plaques in human AD brains. Their role in AD pathogenesis is complex and includes engulfing or degrading amyloid plaques and promoting neurotoxicity through excessive inflammatory cytokine release (Wys-Coray & Rogers, 2012). However, it remains unclear whether microglial phagocytosis Aβ fibrils in vivo (Prokop, Miller, & Heppner, 2013). Moreover, microglial function is impaired in a progressive, Aβ-dependent manner, as shown by a decrease in the phagocytosis of beads in a mouse model of AD (Krabbe et al., 2013). Paradoxically, microglia impairment might be sustained by inflammatory cytokines, which suggests that AD pathology can be accelerated through this vicious circle (Heppner et al., 2015). A recent single-cell RNA-Seq study in an AD mouse model identified a novel microglia subtype which is AD-associated phagocytic cell conserved in mice and human (Keren-Shaul et al., 2017). A list of attractive immune targets has been regarded as having therapeutic values (Heppner et al., 2015).

3.3 Neural stem cells

The adult central nervous system contains resident neural stem cells (NSCs) able to self-renew and to generate new neurons and other neural cell types throughout life. The capacity for neurogenesis of neural stem cells diminishes with age, even in the absence of disease, as seen during bromodeoxyuridine incorporation experiment in aging rat hippocampus (Montaron et al., 1999). Age-related decline of cognitive function is associated with decreased numbers of neural stem cells (Fan, Wheatley, & Villeda, 2017). However, recent two researches (Boldrini et al., 2018; Sorrells et al., 2018) are contradictory to each other on whether endogenous neurogenesis exists in adult human hippocampus and new techniques need to be developed to track the newly generated neurons. Stem cell-based therapeutics, both exogenous (transplantation) and endogenous (via factors such as growth factors that stimulate stem cells), could have important implications for both aging and AD (Limke & Rao, 2002). Most recently, Zhang et al. (2017) showed that mid-aged mice locally implanted with healthy hypothalamic stem/progenitor cells could retard aging and obtain extended lifespan, which they linked to exosomal microRNA mechanisms.

Stem cells may actually only play a limited role in AD, such that part of the neural damage observed during the disease may be attributed to the loss of stem cells’ ability to divide. Interestingly, olfactory identification deficits are suggested to be an early diagnostic marker for AD (Devanand et al., 2000) and stem cells of the subventricular zone could follow the rostral migratory stream to become interneurons in the olfactory bulb (Limke & Rao, 2002). In APPxPS1 mouse AD models, there are only limited numbers of new neurons generated and the capacity of the new granule cells is reduced in a sex-unbalanced manner (Richetin, Petsophysakul, Roybon, Guiard, & Rampon, 2017). NSC transplantation slowed the disease progression in an AD mouse model (Blerton-Jones et al., 2009), while directed expression of a transcription factor, Neurod1, in cycling hippocampal progenitors could produce population of highly connected new neurons and restore spatial memory in AD mouse model (Richetin et al., 2015).

4 SYSTEMS LEVEL EVENTS IN AGING AND AD

4.1 Systemic inflammation

The “inflammaging” theory states that aging is characterized by chronic, low-grade systemic inflammation, and a complex balance between pro- and anti-inflammatory responses. Intrinsic and extrinsic factors responsible for such systemic chronic inflammation, including alterations in chronic viral infections, sex steroids, and debris from other senescent cells, are discussed in two recent reviews (Franceschini, Garagnani, Vitale, Capri, & Salvioli, 2017; Shaw, Goldstein, & Montgomery, 2013).

Although the majority of inflammation in AD is attributed to glia dysfunction, especially in microglia and astrocytes, systemic inflammation shows a strong association with AD, as shown by an interesting experiment: Under systemic immune challenge by the viral mimic polyriboinosinic–polyribocytidilic acid, mice show sporadic AD phenotypes including Aβ plaques and altered Tau phosphorylation (Krstic et al., 2012). In human, there are some similar association studies: Obesity increases the likelihood of systemic inflammation (Almond, Edwards, Barclay, & Johnston, 2013), and white-fat tissue has a high percentage of activated macrophages secreting proinflammatory
cytokines (Bastard et al., 2006); thus, it is not surprising to find that midlife obesity is a risk factor for AD (Whitmer et al., 2008). Data from microbiome studies (see below) have also provided supporting evidence on this issue. Trials in nonsteroidal anti-inflammatory drugs on AD have shown inconsistent results with most ending in failure; however, it is speculated that this may be due to timing and choice of specific anti-inflammatory drugs (Heneka et al., 2015; St-Amour, Cicchetti, & Calon, 2016).

4.2 | Cardiovascular system

The key general vascular modifications occurring during aging (Celermajer et al., 1994; Vita et al., 1990) are endothelial dysfunction and central arterial stiffness. Endothelial dysfunction may be due to diminished bioavailability of nitric oxide (Taddei et al., 2001; Tschudi et al., 1996). Arterial stiffness results primarily from loss of elastic fibers and an increase in collagen (Fritze et al., 2012). Like AD, cardiovascular disease is another aging-related disease that brings a great burden for the patients and healthcare systems (Paneni, Díaz Caiestro, Libby, Lüscher, & Camici, 2017).

There is debate on whether cardiovascular dysfunction can induce AD, because dementia related to cardiovascular conditions can happen without amyloid accumulation, as shown by the following studies: In elderly people (sample size, 942), only midlife dyslipidemia was found to be associated with amyloid deposition, rather than other risk factors including hypertension (Vemuri, Knopman, et al., 2017); and another study from the same group (sample size, 430) found that people with cardiovascular and metabolic conditions had significantly greater neurodegeneration, but their amyloid and tau were at similar levels (Vemuri, Lesnick, et al., 2017). Another follow-up study (sample size, 322; median follow-up, 23.5 years) found that late-life vascular risk factors are not associated with amyloid standardized uptake value ratios (calculated from florbetapir positron emission tomography, in this case, to reflect the brain amyloid deposition). However, when two or more vascular risk factors occur in midlife, then the odds ratio for AD increase to 2.88 (Gottesman et al., 2017).

4.3 | Microbiome

With the advance of next generation of sequencing technology, microbes can be readily sequenced and identified. In a study of female identical twins, frailty as measured by Rockwood Frailty Index has been found to be negatively associated with gut microbiome diversity (Jackson et al., 2016). Among centenarians, the best model of “successful” aging, their gut microbiome showed high diversity of species composition compared to younger elderly adults (Santoro et al., 2017). A recent study even found that when maintained under germ-free conditions, mice do not display an age-related increase in circulating proinflammatory cytokine levels (Thevaranjan et al., 2017); thus, inflamming is controllable in an animal model.

The human gut microbiome has not been investigated for associations with AD yet. In a mouse model of AD, antibiotic treatment decreases Aβ plaque deposition (Minter et al., 2016) and germ-free APP transgenic mice have a drastic reduction in cerebral Aβ amyloid pathology (Harach et al., 2017). Poor dental status has been linked to AD or early signs of AD (Gatz et al., 2006). An early study found that subgingival microbiome is associated with changes in cognitive function (Cockburn et al., 2012). Please refer to Pistollato et al. (2016) and Tremlett, Bauer, Appel-Cresswell, Finlay, and Waubant (2017) as a starting point.

5 | LIFESTYLE ASSOCIATIONS AND INTERVENTIONS FOR AGING AND AD

5.1 | Sleep

An important feature of old age is the decline in sleep, wherein non-rapid eye movement (NREM) slow-wave sleep (SWS) declines are especially significant. Particularly, decline in NREM sleep quality is accelerated in patients with AD relative to age-matched normal people (Prinz et al., 1982). In addition, increased AD symptomatology is related to a parallel sleep deterioration, which appears to be associated with cognitive decline (Liguori et al., 2014). For example, high tau and Aβ protein levels measured in cerebrospinal fluid were correlated with sleep impairment (Liguori et al., 2014). Besides sleep disruption, clinical sleep disorders are strongly comorbid with mild cognitive impairment (MCI) and AD. Over 60% of persons with MCI and AD have one or more sleep disturbances (Ancoli-Israel, Klauber, Butters, Parker, & Kripke, 1991; Guarnieri et al., 2012), with sleep apnea and insomnia being most common.

Insomnia and sleep apnea are not only more prevalent in AD, but increase the risk of developing MCI and AD (Ossorio et al., 2011; Yaffe et al., 2011), suggesting bidirectional links between sleep and Aβ pathology. Furthermore, individuals with sleep apnea had a younger age of MCI or AD onset (Ossorio et al., 2015). By contrast, successfully treating sleep disturbance can delay the age of MCI onset (Ossorio et al., 2015) and improve cognitive function in AD (Ancoli-Israel et al., 2008; dos Santos Moraes et al., 2006). Together, these findings indicate that high-quality sleep can mitigate Alzheimer’s disease pathology. A connection between Aβ and NREM sleep has been found in rodent models (Kang et al., 2009; Roh et al., 2012). Investigating the underlying mechanisms of sleep, a recent study discovered a sleep-dependent role for the lymphatic system in Aβ clearance (Xie et al., 2013). During NREM sleep, glial cells shrink by as much as 60%, facilitating an obviously increased flow of cerebrospinal fluid through interstitial space. This results in enhanced clearance of Aβ and other compounds. Conversely, the waking brain state can contribute to accumulation of Aβ (Kang et al., 2009), specifically through a higher neurometabolic rate relative to NREM sleep (Buchsbbaum et al., 1989). Neurons consume greater levels of oxygen and ATP during wakefulness (Braun et al., 1997; Dworak, McCarley, Kim, Kalinchuk, & Basheer, 2010), while NREM sleep is associated with reduced oxygen consumption and active replenishment of ATP levels (Braun et al., 1997; Dworak et al., 2010). Waking therefore represents a state of higher oxygen, ATP, and glucose
consumption, resulting in high rates of metabolic burdens (Eversen, Henchen, Szabo, & Hogg, 2014). Therefore, without sufficient NREM sleep, the neurotoxicity and oxidative effects of AD pathophysiology are higher (Eversen et al., 2014; Massaad & Klann, 2011; Villafuerte et al., 2015). Furthermore, Aβ accumulation is promoted by oxidative stress (Misonou, Morishima-Kawashima, & Ihara, 2000) and further promotes oxidative stress itself. Thus, sleep loss promoted Aβ aggregation, and Aβ aggregation in turn promotes sleep loss. But, sleep loss also magnifies the effect of Aβ aggregation on neuronal function (Tabuchi et al., 2015).

Detecting selective impairments of NREM sleep quality may represent a novel, noninvasive, relatively inexpensive, and specific biomarker of AD pathology. Frequency-specific quantitative electroencephalographic (EEG) measures of NREM sleep, particularly those in the <1 Hz signature range, may therefore represent an early biomarker of Aβ burden. Compared with other established biomarkers, sleep EEG may significantly contribute to identifying an individual's risk for developing AD years or even decades before onset of clinical symptoms (Jack et al., 2010).

5.2 | Exercise

Physical inactivity is an important risk factor for cognitive decline in aging and for Alzheimer's disease (Norton, Matthews, Barnes, Yaffe, & Brayne, 2014). Conversely, exercise can convey a protective effect (Ahlskog, Geda, Graff-Radford, & Petersen, 2011; Geda et al., 2012; Ngandu et al., 2015; Wirth, Haase, Villeneuve, Vogel, & Jagust, 2014) even if initiated after midlife (Tolppanen et al., 2015). In humans, higher levels of physical activity, as measured by the International Physical Activity Questionnaire, are associated with lower plasma Aβ in APOEε4 noncarriers (Okonkwo et al., 2014; Vidoni et al., 2012).

Besides physical activity, cognitive stimulation can also convey a protective effect against cognitive decline in aging and AD (Anderson-Hanley et al., 2012; Barnes et al., 2013). Spatial navigation training in old age can protect the hippocampus from shrinkage (Lovden et al., 2012). A combination of exercise and cognitive enrichment in mice increases protective effects against synaptotoxicity of Aβ in the hippocampus (Li et al., 2013). However, the benefits from exercise or cognitive stimulation are not consistent across studies (Sexton et al., 2016), and thus, standardized protocols and outcome measures are needed for this field (Duzel, van Praag, & Sendtner, 2016).

5.3 | Metabolism

Aging and many aging-associated disorders involve perturbed energy balance. Metabolism, including glucose regulation and appetite balance, is controlled by both central regulatory inputs (primarily via the hypothalamus) and peripheral signals such as insulin, ghrelin, cholecystokinin, and adipokines (e.g., leptin and adiponectin). It is possible that the association between increased risk of developing AD and excess body weight reflects the potential effect of a diet high in simple sugars and fats to the development of AD. A recent study showed reducing caloric intake increases healthspan, reduces damage in the brain due to aging, and provides greater maintenance of various brain functions (Martin et al., 2008; Martin, Golden, Egan, Mattson, & Maudsley, 2007; Martin, Ji, Maudsley, & Mattson, 2010; Martin, Mattson, & Maudsley, 2006).

There is also a connection between type 2 diabetes mellitus (DM) and AD, and DM individuals have ~2-fold increase in risk of developing AD, compared to patients without the condition (Ott et al., 1999). Furthermore, in the same study, DM requiring insulin treatment was associated with a fourfold increase in incidence of AD. The presence of type 2 DM and the APOEε4 allele together has also been shown to increase the risk of developing AD, to >5-fold, compared to individuals without those two conditions (Peila, Rodriguez, & Launer, 2002). Tau phosphorylation is increased in the cortex and hippocampus of type 2 diabetes mice compared with controls. Recent work has begun to uncover the underlying mechanisms of insulin signaling dysfunction in AD. Clinically, there is a higher density of insulin receptors in the brain of patients with AD compared to control subjects, possibly reflecting upregulation of the receptor in an attempt to compensate for the decreased functionality of insulin (Frolich et al., 1998). By contrast, some studies reported decreased insulin receptor binding in individuals with AD in comparison with age-matched control (Arnold et al., 2018; Rivera et al., 2005; Steen et al., 2005). For example, reduced insulin, insulin receptor, IGFl and IGF2, reduced total IRS1 mRNA expression, and reduced protein indicators of downstream insulin signaling activity (including p85-associated IRS1, phosphorylated AKT) have been reported in postmortem AD brain (Steen et al., 2005). Although there are some controversial results about insulin receptor concentration, insulin resistance in AD has been demonstrated a novel ex vivo insulin signaling stimulation experiment (Arnold et al., 2018; Talbot et al., 2012). Insulin may affect Aβ degradation via an insulin-degrading metalloprotease. It has been observed that the decreased activity, low concentrations, and small amounts of mRNA of insulin-degrading enzyme in brains of patients with AD and knockout mice that lack the enzyme have reduced degradation of Aβ and insulin in brain (Lam & Lu, 2007; Li et al., 2002; Shanley, Irving, & Harvey, 2001). Similarly, insulin resistance is commonly observed in older adults (Barzilai, Huffman, Muzumdar, & Bartke, 2012; Morley, 2008). Insulin resistance usually caused the unrestrained hepatic gluconeogenesis, adipose lipogenesis, and defective glycogen synthesis and glucose uptake in skeletal muscle. In addition, the proinflammatory cytokines, which is increased with aging, are involved in insulin action (Sepe, Tchkonia, Thomou, Zamboni, & Kirkland, 2011). Adiponec-tin is also a metabolic regulator that can be linked to aging due to its effect on insulin sensitivity (Berg & Scherer, 2005). Meanwhile, aging is strongly associated with a progressive loss in mitochondrial function (Dirks, Hofer, Marzetti, Pahor, & Leeuwenburgh, 2006). Besides insulin, it was found that lower plasma leptin levels were associated with a higher risk of incident AD (Lieb et al., 2009). In addition, glucagon-like peptide 1 can reduce Aβ levels in vivo and
decreases levels of amyloid precursor protein in cultured neuronal cells (Perry et al., 2003).

Brains with AD display a higher occurrence of “adipose inclusions” or “lipoid granules”, suggesting aberrant lipid metabolism (Foley, 2010). In the brain, cholesterol is present mainly in its unesterified form in myelin sheaths and the cellular membranes of glial cells and neurons (Dietschy & Turley, 2001). As the blood-brain barrier limits efficient exchange between brain and plasma lipoproteins, the majority of brain cholesterol is derived from de novo biosynthesis, rather than from plasma LDL (Dietschy & Turley, 2001). Excess free cholesterol in the cell is converted into cholesteryl esters by the enzyme sterol O-acyltransferase 1 (ACAT1; also known as acyl CoA-cholesterol acyltransferase 1), followed by accumulation in intracellular lipid droplets or efflux through the plasma membrane into the extracellular environment (Chang, Chang, Ohgami, & Yamauchi, 2006). Increasing levels of cholesteryl esters enhance Aβ release in cultured cells, whereas pharmacological inhibition of ACAT1 (for example, CP-113, 818 treatment) can lead to the reduction in both Aβ and cholesteryl ester (Bhattacharyya & Kovacs, 2010; Hutter-Paier et al., 2004; Puglielli et al., 2001).

Cholesterol regulates Aβ generation through regulating secretase activities. By reducing cellular cholesterol level through lovastatin and methyl-β-cyclodextrin, the formation of Aβ is inhibited (Hartmann, Kuchenbecker, & Grimm, 2007; Simons et al., 1998; Vetrivel & Thinakaran, 2010). Cholesterol levels can also directly regulate β-secretase-mediated production of Aβ (Fassbender et al., 2001; Simons et al., 1998; Wahrle et al., 2002). Inclusion of cholesterol or sphingolipids in phosphatidylcholine-containing vesicles leads to increased γ-secretase activity (Osawa et al., 2008; Osenkowski, Ye, Wang, Wolfe, & Selkoe, 2008). Cholesterol depletion also decreases the association of BACE1 with lipid rafts resulting in decreased processing of APP and BACE1 in lipid raft domains, as well as their rapid endocytosis (Marquer et al., 2011). Introduction of a glycosylphosphatidylinositol anchor, a targeting motif for lipid raft localization, into the BACE1 sequence strongly promotes amyloidogenic processing of APP (Hartmann et al., 2007; Simons et al., 1998), further supporting the key role of the BACE1 association in Aβ generation. In conclusion, these studies suggest that cholesterol plays an important role in Aβ production by altering the levels of BACE1 in lipid rafts. Beyond cholesterol, some other lipids such as sphingolipids, isoprenoids, and phospholipids also play important roles in Aβ production (Hannun & Obeid, 2008; Hooff, Wood, Muller, & Eckert, 2010; Petanceska & Gandy, 1999).

| Molecular link between aging and AD | Cell type composition of aging and AD | Systems level of aging and AD | Lifestyle and intervention of aging and AD |
|-----------------------------------|-------------------------------------|-------------------------------|----------------------------------------|
| **Genetic susceptibility**        | **Neurons**                         | **Viral mimic induction; obesity association** | **Sleep**                             |
| APP, PSEN1, PSEN2, TREM, CD33, CD1| Marked by synaptic loss             | Inflamming                    | Sleep apnea; insomnia; NREM            |
| **DNA methylation**              | **Glia**                            | **Proinflammatory phenotypes; microglial dystrophy** | **Metabolic**                         |
| Epigenetic clock                 | Reactive astrogliosis; microglia pathogenesis | Proinflammatory environment   | Glucagon-like peptide 1; phospholipids; leptin; sphingolipids; cholesterol; isoprenoids |
| **Histone modifications**        | **Neural stem cells**               | **Endothelial dysfunction; central arterial stiffness** | Adiponectin; mitochondria              |
| HDACi reverses cognitive defects | Olfactory deficits; slow progression | **Decreased gut microbiome diversity** | **Insulin**                           |
| **RNA**                          | **Systemic inflammation**           | **Germ-free condition control inflamming or AD phenotype** | **Exercise**                          |
| Diagnostic tools; BACE1-AS and BC200|lin-4 and Dicer                      | **Cognitive stimulation; physical activity** | Cognitive stimulation; physical activity|

## Table 1

Summary of commonalities and differences between aging and Alzheimer's disease (AD)

| AD | Aging | Common |
|----|-------|--------|
| Molecular link between aging and AD | | |
| Genetic susceptibility | APP, PSEN1, PSEN2, TREM, CD33, CD1 | FOXA3A | APOE |
| DNA methylation | Epigenetic clock | Association of 5mC and 5nmC | Overexpression of Dnmt3a2 improves the cognitive abilities of aged mice |
| Histone modifications | HDACi reverses cognitive defects | Loss of repressive marks; gain of activating marks | Acetylation |
| RNA | Diagnostic tools; BACE1-AS and BC200 | lin-4 and Dicer | RNA editing decrease |
| Cell type composition of aging and AD | | |
| Neurons | Marked by synaptic loss | No obvious neuron loss | |
| Glia | Reactive astrogliosis; microglia pathogenesis | Proinflammatory phenotypes; microglial dystrophy | Proinflammatory environment |
| Neural stem cells | Olfactory deficits; slow progression | Stem cell capacity loss; extend lifespan | NSC implantation |
| Systems level of aging and AD | | |
| Systemic inflammation | Viral mimic induction; obesity association | Inflamming | Strong association |
| Cardiovascular system | Midlife vascular risk association | Endothelial dysfunction; central arterial stiffness | |
| Antibiotic treatment; dental status | Decreased gut microbiome diversity | Germ-free condition control inflamming or AD phenotype | |
| Lifestyle and intervention of aging and AD | | |
| Sleep | | Sleep apnea; insomnia; NREM |
| Metabolic | Glucagon-like peptide 1; phospholipids; leptin; sphingolipids; cholesterol; isoprenoids | Adiponectin; mitochondria |
| Exercise | | Cognitive stimulation; physical activity |
From the above comparison and association studies, we find that AD, in many ways—but not all—accelerated aging. At the molecular level, GWAS of AD and aging hit the same gene, APOE, with the same effect on the two different alleles. The aging field could actually learn from the AD field; wherein, better diagnoses have led to more robust GWAS results, for example, biological age is not taken into consideration for aging GWAS and lifestyle and environment causes need to be controlled or stratified for more repeatable result. DNA methylation and histone modifications show association with aging and AD. Specifically, HDAC inhibition could reverse the cognitive deficits in AD. Noncoding RNA and RNA modifications emerged as a new research focus in aging and AD; so far, no miRNA and lncRNA changes are known to overlap between aging and AD, while changes in RNA editing show a similar pattern in the aging and AD (overall editing levels decrease in both cases).

The cell type composition changes in aging and AD highlight systems level alterations in AD and aging. A significant difference between aging and AD is that the number of neurons does not change very much during aging, but neuron and synapse loss is a hallmark of AD. Microglia gained much attention due to new highly convincing GWAS, which included the association to TREM and CD33. Overall, for glia cell types, there is a proinflammatory environment promoted by aging, which is much more exacerbated in AD.

The surveys at the system levels are still lagging behind, but the circulatory system and the “brain–gut axis” provide links between the brain and other parts of the body as illustrated by the fascinating example that mice growing under germ-free conditions show low inflammation level and reduced cerebral Aβ. Overall, chronic inflammation seems to a strong commonality between aging and AD, and if it could be precisely controlled from either the aging or AD perspective based on research products from either field, such treatment could benefit both the aging and AD process and transform the overall landscape of aging and AD.

Among many lifestyle associations and interventions for aging and AD, sleep is clearly strongly associated with brain aging and AD, while the benefits of exercise are still controversial. Metabolic changes in AD are pervasive; however, it converges with aging on insulin and lipid changes; in particular, cholesterol is positively correlated with aging and clearly related to AD pathology.

In summary, aging and AD research are two fields that are intrinsically linked (as summarized in Table 1). Many interventions of aging, such as exercise and calorie restriction (Gunn-Moore, Kaidanovich-Beilin, Gallego Iradi, Gunn-Moore, & Lovestone, 2018), can alleviate AD phenotypes. Drugs and treatments for AD can also slow down aging phenotypes, such as treatments with HDAC inhibitors and neural stem cell transplantation. Although these interventions are validated in mouse models so far, more evidence is in urgent need in human or other primates.

ACKNOWLEDGMENTS

This work was supported by grants from China Ministry of Science and Technology 2015CB964803 and 2016YFE0108700; National Natural Science Foundation of China 91749205, 31210103916, and 91519330; and Chinese Academy of Sciences XDB19020301 and XDA01010303 to J.D.J.H.

REFERENCES

Ahlskog, J. E., Geda, Y. E., Graff-Radford, N. R., & Petersen, R. C. (2011). Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging. Mayo Clinic Proceedings, 86, 876–884. https://doi.org/10.4065/mcp.2011.0252

Almond, M. H., Edwards, M. R., Barclay, W. S., & Johnston, S. L. (2013). Obesity and susceptibility to severe outcomes following respiratory viral infection. Thorax, 68, 684–686. https://doi.org/10.1136/thoraxjnlt-2012-203009

Ancoli-Israel, S., Krauser, M. R., Butters, N., Parker, L., & Kripke, D. F. (1991). Dementia in institutionalized elderly: Relation to sleep apnea. Journal of the American Geriatrics Society, 39, 258–263. https://doi.org/10.1111/j.1532-5415.1991.tb01647.x

Ancoli-Israel, S., Palmer, B. W., Cooke, J. R., Corey-Bloom, J., Fiorentino, L., Natarajan, L., ... Loredo, J. S. (2008). Cognitive effects of treating obstructive sleep apnea in Alzheimer’s disease: A randomized controlled study. Journal of the American Geriatrics Society, 56, 2076–2081. https://doi.org/10.1111/j.1532-5415.2008.01934.x

Anderson-Hanley, C., Arciero, P. J., Brickman, A. M., Nimon, J. P., Okuma, N., Westen, S. C., ... Zimmerman, E. A. (2012). Exergaming and older adult cognition: A cluster randomized clinical trial. American Journal of Preventive Medicine, 42, 109–119. https://doi.org/10.1016/j.amepre.2011.10.016

Anselmi, C. V., Malovini, A., Roncarati, R., Novelli, V., Villa, F., Condorelli, G., ... Puca, A. A. (2009). Association of the FOXO3A locus with extreme longevity in a southern Italian centenarian study. Rejuvenation Research, 12, 95–104. https://doi.org/10.1089/rej.2008.0827

Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H. Y., Ahima, R. S., ... Nathan, D. M. (2018). Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums. Nature Reviews Neurology, 14, 168–181. https://doi.org/10.1038/nrneurol.2017.185

Barau, J., Teissandier, A., Zamudio, N., Roy, S., Naless, V., Héraut, Y., ... Bourchis, D. (2016). The DNA methyltransferase DNMT3C protects male germ cells from transposon activity. Science (New York, NY), 354, 909–912. https://doi.org/10.1126/science.aah5143

Barnes, D. E., Santos-Modestitt, W., Poelke, G., Kramer, A. F., Castro, C., Middleton, L. E., ... Yaffe, K. (2013). The Mental Activity and eXercise (MAX) trial: A randomized controlled trial to enhance cognitive function in older adults. Jama Intern Med, 173, 797–804. https://doi.org/10.1001/jamainternmed.2013.189

Barzilai, N., Huffman, D. M., Muzumdar, R. H., & Bartke, A. (2012). The critical role of metabolic pathways in aging. Diabetes, 61, 1315–1322. https://doi.org/10.2337/db11-1300

Bastard, J.-P., Maachi, M., Lagathu, C., Kim, M. J., Caron, M., Vidal, H., ... Feve, B. (2006). Recent advances in the relationship between obesity, inflammation, and insulin resistance. European Cytokine Network, 17, 4–12.

Benito, E., Urbanke, H., Ramachandran, B., Barth, J., Halder, R., Awasthi, A., ... Fischer, A. (2015). HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models. Journal of Clinical Investigation, 125, 3572–3584. https://doi.org/10.1172/JCI79942
Hannun, Y. A., & Obeid, L. M. (2008). Principles of bioactive lipid signalling: Lessons from sphingolipids. *Nature Reviews Molecular Cell Biology*, 9, 139–150. https://doi.org/10.1038/nrm2329

Harach, T., Marungruang, N., Duthilleul, N., Cheatham, V., Mc Coy, K. D., Frisoni, G., ... Bolmont, T. (2017). Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. *Scientific Reports*, 7, 41802. https://doi.org/10.1038/srep41802

Harry, G. J. (2013). Microglia during development and aging. *Pharmacology & Therapeutics*, 139, 313–326. https://doi.org/10.1016/j.pharmthera.2013.04.013

Hartmann, T., Kuchenbecker, J., & Grimm, M. O. (2007). Alzheimer’s disease: The lipid connection. *Journal of Neurochemistry*, 103(Suppl 1), 159–170. https://doi.org/10.1111/j.1471-4159.2007.07417.x

Hattori, C., Asai, M., Onishi, H., Sasagawa, N., Hashimoto, Y., Salido, T. C., ... Ishiura, S. (2006). BACE1 interacts with lipid raft proteins. *Journal of Neuroscience Research*, 84, 912–917. https://doi.org/10.1002/jnr.20981

Heneka, T. M., Carson, M. J., Khoury, J. E., Landreth, G. E., Broserson, F., Feinstein, D. L., ... Kummer, M. P. (2015). Neuroinflammation in Alzheimer’s disease. *The Lancet Neurology*, 14, 388–405. https://doi.org/10.1016/S1474-4422(15)70016-5

Hepper, F. L., Ransohoff, R. M., & Becher, B. (2015). Immune attack: The role of inflammation in Alzheimer disease. *Nature Reviews Neuroscience*, 16, 358–372. https://doi.org/10.1038/nrn3880

Heyn, H., Li, N., Ferreira, H. J., Morán, S., Pisano, D. G., Gomez, A., ... Esteller, M. (2012). Distinct DNA methylomes of newborns and centenarians. *Proceedings of the National Academy of Sciences of the United States of America*, 109, 10522–10527. https://doi.org/10.1073/pnas.1106581109

Hooft, G. P., Wood, W. G., Muller, W. E., & Eckert, G. P. (2010). Isoprenoids, small GTPases and Alzheimer’s disease. *Biochimica Et Biophysica Acta*, 1801, 896–905. https://doi.org/10.1016/j.bbalip.2010.03.014

Hutter-Paier, B., Huttunen, H. J., Puglielli, L., Eckman, C. B., Kim, D. Y., Hofmeister, A., ... Kovacs, D. M. (2004). The ACAT inhibitor CP-118,818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease. *Neuron*, 44, 227–238. https://doi.org/10.1016/j.neuron.2004.08.043

Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Sweeney, J. A., ... Zhang, Y. (2011). Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxycytosine. *Science (New York, NY)*, 333, 1300–1303. https://doi.org/10.1126/science.1210597

Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., ... Trojanowski, J. Q. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. *The Lancet Neurology*, 9, 119–128. https://doi.org/10.1016/S1474-4220(09)70299-6

Jackson, M. A., Jackson, M., Jeffery, I. B., Beaumont, M., Bell, J. T., Clark, A. G., ... Stevens, C. J. (2016). Signatures of early frailty in the gut microbiota. *Genome Medicine*, 8, 8. https://doi.org/10.1186/s13073-016-0262-7

Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, E., ... Stefansson, K. (2013). Variant of TREM2 associated with the risk of Alzheimer’s disease. *The New England Journal of Medicine*, 368, 107–116. https://doi.org/10.1056/NEJMoa1211103

Junn, E., & Mouradian, M. M. (2012). MicroRNAs in neurodegenerative diseases and their therapeutic potential. *Pharmacology & Therapeutics*, 133, 142–150. https://doi.org/10.1016/j.pharmthera.2011.10.002

Kang, J.-E., Lim, M. M., Bateman, R. J., Lee, J. J., Smyth, L. P., Cirrito, J. R., ... Holtzman, D. M. (2009). Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle. *Science*, 326, 1005–1007. https://doi.org/10.1126/science.1180962

Karch, C. M., & Goate, A. M. (2015). Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. *Biological Psychiatry*, 77, 43–51. https://doi.org/10.1016/j.biopsych.2014.05.006
to brain reductions in acetylcholine. Journal of Alzheimer's Disease, 8, 247–268. https://doi.org/10.3233/JAD-2005-8304
Roh, J. H., Huang, Y., Bero, A. W., Kasten, T., Stewart, F. R., Bateman, R. J., & Holtzman, D. M. (2012). Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer’s disease pathology. Science Translational Medicine, 4, 150ra122-150ra122. https://doi.org/10.1126/scitranslmed.3004291
Salter, M. W., & Stevens, B. (2017). Microglia emerge as central players in brain disease. Nature Medicine, 23, 1018–1027. https://doi.org/10.1038/nm.4397
Santoro, A., Ostan, R., Candela, M., Biagi, E., Brigidi, P., Capri, M., & Franceschi, C. (2017). Gut microbiota changes in the extreme decades of human life: A focus on centenarians. Cellular and Molecular Life Sciences, 75(1), 129–148. https://doi.org/10.1007/s00018-017-2674-y
Scheff, S. W., & Price, D. A. (2006). Alzheimer’s disease-related alterations in synaptic density: Neocortex and hippocampus. Journal of Alzheimer’s Disease, 9, 101–115. https://doi.org/10.3233/JAD-2006-95312
Sen, P., Shah, P. P., Nativio, R., & Berger, S. L. (2016). Epigenetic mechanisms of longevity and aging. Cell, 166, 822–839. https://doi.org/10.1016/j.cell.2016.07.050
Sepe, A., Tchkonia, T., Thomou, T., Zamboni, M., & Kirkland, J. L. (2011). Aging and regional differences in fat cell progenitors - a mini-review. Gerontology, 57, 66–75. https://doi.org/10.1159/000279755
Seripa, D., Franceschi, M., Matera, M. G., Panza, F., Kehoe, P. G., Gravina, C., … Pilotta, A. (2006). Sex differences in the association of apolipoprotein E and angiotensin-converting enzyme gene polymorphisms with healthy aging and longevity: A population-based study from Southern Italy. Journals of Gerontology Series A, Biological and Medical Sciences, 61, 918–923. https://doi.org/10.1093/gerona/61.9.918
Sexton, C. E., Betts, J. F., Demmitz, N., Dawes, H., Ebmeier, K. P., & Johansen-Berg, H. (2016). A systematic review of MRI studies examining the relationship between physical fitness and activity and the white matter of the ageing brain. NeuroImage, 131, 81–90. https://doi.org/10.1016/j.neuroimage.2015.09.071
Shanley, L. J., Irving, A. J., & Harvey, J. (2001). Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity. Journal of Neuroscience, 21, Rc186. https://doi.org/10.1523/JNEUROSCI.21-24-j0001.2001
Shaw, A. C., Goldstein, D. R., & Montgomery, R. R. (2013). Age
Sorrells, S. F., Paredes, M. F., Cebrian, E., Terry, B. M., Rivera, E. J., Cannon, J. L., Neely, T. R., Tavares, R., … de la Monte, S. M. (2005). Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—is this type 3 diabetes? Journal of Alzheimer's Disease, 7, 63–80. https://doi.org/10.3233/JAD-2005-7107
Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., … Roses, A. D. (1993). Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proceedings of the National Academy of Sciences, 90, 8098–8102. https://doi.org/10.1073/pnas.90.17.8098
Tabuchi, M., Lane, S. R., Liu, S., Liu, Q., Zhang, J., Spira, A. P., & Wu, M. N. (2015). Sleep interacts with Aβ to modulate intrinsic excitability. Current Biology, 25, 702–712. https://doi.org/10.1016/j.cub.2015.01.016
Taddei, S., Virdis, A., Ghiadoni, L., Salvetti, G., Bernini, G., Magagna, A., & Salvetti, A. (2001). Age-related reduction of NO availability and oxidative stress in humans. Hypertension, 39, 274–279. https://doi.org/10.1161/01.HYP.38.2.274
Talbot, K., Wang, H. Y., Kazi, H., Han, L. Y., Bakshi, K. P., Stucky, A., … Arnold, S. E. (2012). Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. Journal of Clinical Investigation, 122, 1316–1338. https://doi.org/10.1172/JCI59903
Tan, L., Yu, J. T., Hu, N., & Tan, L. (2013). Non-coding RNAs in Alzheimer’s disease. Molecular Neurobiology, 47, 382–393. https://doi.org/10.1007/s12031-013-8359-5
Thevaranjan, N., Puchta, A., Schulz, C., Naidoo, A., Szamosi, J. C., Ver- schoor, C. P., … Bowdish, D. M. E. (2017). Age-associated microbial dysbiosis promotes intestinal permeability, systemic inflammation, and macrophage dysfunction. Cell Host & Microbe, 21, 455–466.e454. https://doi.org/10.1016/j.chom.2017.03.002
Tolpapan, A. M., Solomon, A., Kulmana, J., Kareholt, I., Ngrund, T., Rusa- nen, M., … Kivipelto, M. (2015). Leisure-time physical activity from mid- to late life, body mass index, and risk of dementia. Alzheimer’s & Dementia : the Journal of the Alzheimer’s Association, 11, 434–443.e436. https://doi.org/10.1016/j.jalz.2014.01.008
Tremlett, H., Bauer, K. C., Appel-Cresswell, S., Finlay, B. B., & Waubant, E. (2017). The gut microbiome in human neurological disease: A review: Gut microbiome. Annals of Neurology, 81(3), 369–382. https://doi.org/10.1002/ana24901
Tschudi, M. R., Barton, M., Bersinger, N. A., Moreau, P., Cosentino, F., Noll, E., … Lüscher, T. F. (1996). Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. Journal of Clinical Investigation, 98(4), 899–905. https://doi.org/10.1172/JCI118872
Vemuri, P., Knopman, D. S., Lesnick, T. G., Przybelski, S. A., Mielke, M. M., Graff-Radford, J., … Jack, C. R. (2017). Evaluation of amyloid protective factors and Alzheimer Disease neurodegeneration protective factors in elderly individuals. JAMA Neurology, 74(6), 718–726. https://doi.org/10.1001/jamaneurol.2017.0244
Vemuri, P., Lesnick, T. G., Przybelski, S. A., Knopman, D. S., Lowe, V. J., Graff-Radford, J., … Jack, C. R. (2017). Age, vascular health, and Alzheimer’s disease biomarkers in an elderly sample. Annals of Neurology, 82, 706–718. https://doi.org/10.1002/ana.25071
Vetrivel, K. S., & Thinakaran, G. (2010). Membrane rafts in Alzheimer’s disease. Current Biology, 20, 74–466.e454. https://doi.org/10.1016/j.cub.2010.03.007
Vidoni, E. D., Van Sciver, A., Johnson, D. K., He, J., Homea, R., Haines, B., … Burns, J. M. (2012). A community-based approach to trials of aerobic exercise in aging and Alzheimer’s disease. Contemporary Clinical Trials, 33, 1105–1116. https://doi.org/10.1016/j.cct.2012.08.002
Villafuerte, G., Miguel-Puga, A., Murillo Rodriguez, E., Machado, S., Manjarrez, E., & Arias-Carrión, O. (2015). Sleep deprivation and oxidative stress in animal models: A systematic review. Oxidative Medicine and Cellular Longevity, 2015, 1–15. https://doi.org/10.1155/2015/234952
Vita, J. A., Treasure, C. B., Nabel, E. G., McLenachan, J. M., Fish, R. D., Yeung, A. C., … Ganz, P. (1990). Coronary vasomotor response to
acetylcholine relates to risk factors for coronary artery disease. Circulation, 81, 491–497. https://doi.org/10.1161/01.CIR.81.2.491

Wahrle, S., Das, P., Nyborg, A. C., McLendon, C., Shoji, M., Kawarabayashi, T., … Golde, T. E. (2002). Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich microdomain membranes. Neurobiology of Diseases, 9, 11–23. https://doi.org/10.1006/ndbi.2001.0470

Whitmer, R. A., Gustafson, D. R., Barrett-Connor, E., Haan, M. N., Gunderson, E. P., & Yaffe, K. (2008). Central obesity and increased risk of dementia more than three decades later. Neurology, 71, 1057–1064. https://doi.org/10.1212/01.wnl.0000306313.89165.ef

Willcox, B. J., Donlon, T. A., He, Q., Chen, R., Grove, J. S., Yano, K., … Curb, J. D. (2008). FOXO3A genotype is strongly associated with human longevity. Proceedings of the National Academy of Sciences of the United States of America, 105, 13987–13992. https://doi.org/10.1073/pnas.0801030105

Wirth, M., Haase, C. M., Villeneuve, S., Vogel, J., & Jagust, W. J. (2014). Neuroprotective pathways: Lifestyle activity, brain pathology, and cognition in cognitively normal older adults. Neurobiology of Aging, 35, 1873–1882. https://doi.org/10.1016/j.neurobiolaging.2014.02.015

Wyss-Coray, T., & Rogers, J. (2012). Inflammation in Alzheimer disease—a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med, 2, a006346. https://doi.org/10.1101/cshperspect.a006346

Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., … Nedergaard, M. (2013). Sleep drives metabolite clearance from the adult brain. Science, 342, 373–377. https://doi.org/10.1126/science.1241224

Yaffe, K., Laffan, A. M., Harrison, S. L., Redline, S., Spira, A. P., Ensrud, K. E., … Stone, K. L. (2011). Sleep disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. Jamae Journal of the American Medical Association, 306, 613–619. https://doi.org/10.1001/jama.2011.1115

Yamada, T., Akiyama, H., & McGeer, P. L. (1990). Complement-activated oligodendroglia: A new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d. Neuroscience Letters, 112, 161–166. https://doi.org/10.1016/0304-3940(90)90196-G

Yu, L., Chibnik, L. B., Yang, J., McCabe, C., Xu, J., Schneider, J. A., … Bennett, D. A. (2016). Methylation profiles in peripheral blood CD4+ lymphocytes versus brain: The relation to Alzheimer’s disease pathology. Alzheimer’s & Dementia: the Journal of the Alzheimer’s Association, 12, 942–951. https://doi.org/10.1016/j.jalz.2016.02.009

Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., … Emilsson, V. (2013). Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell, 153, 707–720. https://doi.org/10.1016/j.cell.2013.03.030

Zhang, Y., Kim, M. S., Jia, B., Yan, J., Zuniga-Hertz, J. P., Han, C., & Cai, D. (2017). Hypothalamic stem cells control ageing speed partly through exosomal miRNAs. Nature, 548, 52–57. https://doi.org/10.1038/nature23282

Zhang, K., Schrag, M., Crofton, A., Trivedi, R., Vinters, H., & Kirsch, W. (2012). Targeted proteomics for quantification of histone acetylation in Alzheimer’s disease. Proteomics, 12, 1261–1268. https://doi.org/10.1002/pmic.201200010

Zhao, H.-Q., Zhang, P., Gao, H., He, X., Dou, Y., Huang, A. Y., … Wei, L. (2015). Profiling the RNA editomes of wild-type C. elegans and ADAR mutants. Genome Research, 25, 66–75. https://doi.org/10.1101/gr.176107.114

Zhao, J., Zhu, Y., Yang, J., Li, L., Wu, H., De Jager, P. L., … Bennett, D. A. (2017). A genome-wide profiling of brain DNA hydroxymethylation in Alzheimer’s disease. Alzheimer’s & Dementia: the Journal of the Alzheimer’s Association, 13, 674–688. https://doi.org/10.1016/j.jalz.2016.10.004

How to cite this article: Xia X, Jiang Q, McDermott J, Han J-DJ. Aging and Alzheimer’s disease: Comparison and associations from molecular to system level. Aging Cell. 2018;17:e12802. https://doi.org/10.1111/ace12802